logo
Share SHARE
FONT-SIZE Plus   Neg

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple Inc. (AAPL) has scheduled its annual hardware event on Wednesday, September 7, when the tech giant is expected to unveil the most-awaited smartphone of the year-- iPhone 7. Apple has sent out invitation to the media and published the event on its website with a simple title "See you on the 7th." Although,... Starbucks Corp. (SBUX) has opened its first outlet on the island of Trinidad, as the coffee giant continues its Caribbean expansion. The new store is now open in San Fernando, Trinidad's SouthPark Entertainment Complex. Starbucks opened its first store in the Caribbean region in San Juan, Puerto... Conroe, Texas-based Country Fresh LLC., is recalling 30,000 cases of various fresh-cut vegetable products, due to a potential contamination of Listeria. The contamination was discovered during a routine sample taken at a retail store by the Georgia Department of Agriculture, which revealed the finished...
comments powered by Disqus
Follow RTT